Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Account Payables
Amounts the company owes suppliers for goods and services received.
Citius Oncology, Inc.NASDAQ: CTOR
Account Payables · Q2 FY2026 · quarter ended Mar 2026
Account payables rises 15.7% from a year ago
Account payables stood at $8.88M at the end of Q2 FY2026, up 15.7% from a year earlier and down 15.0% from the prior quarter. Over 3 fiscal years it compounded at +423.4% a year.
Context
- Account payables amounted to 8.8% of total assets at the end of Q2 FY2026, up 0.4 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +15.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 13.23M USD
- Year-over-year change
- +256.6%
- 3-year CAGR
- +423.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 13.23M | +256.6% |
| FY2024 | 2024-09-30 | 3.71M | +187.9% |
| FY2023 | 2023-09-30 | 1.29M | +1296.4% |
| FY2022 | 2022-09-30 | 92.31K | — |
Account Payables vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 account payables of $8.88M is the 5th highest of the 10 companies compared; the peer median is $3.28M.
- Its year-over-year change of +15.7% is the 4th highest of 10, against a peer median of -7.3%.
- Account payables amounts to 8.8% of total assets for CTOR, versus a peer median of 13.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $101.58M | +77.4% | +116.9% | 34.6% | |
| Mar 2026 | $13.08M | +160.5% | +105.4% | 19.5% | |
| Mar 2026 | $11.78M | -7.3% | -26.7% | 13.6% | |
| Mar 2026 | $10.1M | +30.2% | +51.8% | 15.2% | |
CTORCitius Oncology, Inc. | Mar 2026 | $8.88M | +15.7% | +423.4% | 8.8% |
| Mar 2026 | $3.28M | -21.8% | -31.5% | 1.2% | |
| Mar 2026 | $2.34M | +7.8% | -54.1% | 2.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $1.2M | -54.6% | -10.6% | 13.5% |
| Mar 2026 | $1.04M | -72.1% | +42.5% | 0.2% | |
| Mar 2026 | $217K | -87.7% | +3.9% | 0.4% | |
| Peer median (excluding CTOR) | $3.28M | -7.3% | +3.9% | 13.5% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.